Razpipadon

Razpipadon
Clinical data
Other names	CVL-871; CVL871; PF-06669571; PF06669571; PF-6669571; PF6669571; PW-0464; PW0464
Routes of; administration	Oral
Drug class	Dopamine receptor agonist; Dopamine D1 and D5 receptor agonist
Identifiers
	IUPAC name 6-[4-[3-(difluoromethoxy)pyridin-2-yl]oxy-2-methylphenyl]-1,5-dimethylpyrimidine-2,4-dione;
CAS Number	1643489-35-3;
PubChem CID	86764103;
ChemSpider	58945356;
UNII	6X6XF88J2M;
ChEMBL	ChEMBL3697578;
Chemical and physical data
Formula	C19H17F2N3O4
Molar mass	389.359 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1)OC2=C(C=CC=N2)OC(F)F)C3=C(C(=O)NC(=O)N3C)C;
	InChI InChI=1S/C19H17F2N3O4/c1-10-9-12(27-17-14(28-18(20)21)5-4-8-22-17)6-7-13(10)15-11(2)16(25)23-19(26)24(15)3/h4-9,18H,1-3H3,(H,23,25,26); Key:ZXIPVZWZRQCIRW-UHFFFAOYSA-N;

Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.^[1]^[2]^[3]^[4]^[5] It is taken orally.^[1]

The drug was originated by Pfizer and is under development by Cerevel Therapeutics.^[1]^[2] As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.^[1] It was also previously under development for Parkinson's disease and cognition disorders, but development for these indications was discontinued.^[2]

References

1 2 3 4 5 6 "CVL 871 - AdisInsight".
1 2 3 "PF 06669571". AdisInsight. 30 October 2021. Retrieved 7 June 2026.
1 2 Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ (December 2020). "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci. 3 (6): 1042–1062. doi:10.1021/acsptsci.0c00117. PMC 7737210. PMID 33344888.
↑ Wang HJ, Chinna-Meyyappan A, Feldman OJ, Lanctôt KL (June 2024). "Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease". Expert Opin Emerg Drugs: 1–15. doi:10.1080/14728214.2024.2363215. PMID 38822731.
↑ Dolphin H, Dyer AH, McHale C, O'Dowd S, Kennelly SP (July 2023). "An Update on Apathy in Alzheimer's Disease". Geriatrics. 8 (4): 75. doi:10.3390/geriatrics8040075. PMC 10366907. PMID 37489323.
↑ "CVL-871 - Cerevel Therapeutics". 2 January 2020.

Clinical data

Other names	CVL-871; CVL871; PF-06669571; PF06669571; PF-6669571; PF6669571; PW-0464; PW0464
Routes of administration	Oral^[1]
Drug class	Dopamine receptor agonist; Dopamine D₁ and D₅ receptor agonist
Identifiers
IUPAC name 6-[4-[3-(difluoromethoxy)pyridin-2-yl]oxy-2-methylphenyl]-1,5-dimethylpyrimidine-2,4-dione
CAS Number	1643489-35-3
PubChem CID	86764103
ChemSpider	58945356
UNII	6X6XF88J2M
ChEMBL	ChEMBL3697578
Chemical and physical data
Formula	C₁₉H₁₇F₂N₃O₄
Molar mass	389.359 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1)OC2=C(C=CC=N2)OC(F)F)C3=C(C(=O)NC(=O)N3C)C
InChI InChI=1S/C19H17F2N3O4/c1-10-9-12(27-17-14(28-18(20)21)5-4-8-22-17)6-7-13(10)15-11(2)16(25)23-19(26)24(15)3/h4-9,18H,1-3H3,(H,23,25,26) Key:ZXIPVZWZRQCIRW-UHFFFAOYSA-N